Edward Pershing - Oct 27, 2023 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
Director
Signature
/s/ Edward Pershing
Stock symbol
PVCT
Transactions as of
Oct 27, 2023
Transactions value $
-$7,500
Form type
4
Date filed
10/27/2023, 05:55 PM
Previous filing
Oct 19, 2023
Next filing
Nov 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Unsecured Convertible Promissory Note Options Exercise -$7.5K $1.96M Oct 27, 2023 Series D-1 Convertible Preferred Stock 2.83K $2.86 Direct F3, F4
transaction PVCT Series D-1 Convertible Preferred Stock Options Exercise $0 +2.83K +0.4% $0.00 713K Oct 27, 2023 Common Stock 28.3K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
F3 The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "2022 Note") at any time while the 2022 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Note. The 2022 Note was issued pursuant to the Issuer's 2022 Financing.
F4 On October 27, 2023, the 2022 Note was converted into 2,832 shares of Series D-1 Preferred Stock.